Targeting ATR in patients with cancer
Nature Reviews Clinical Oncology, Published online: 20 February 2024; doi:10.1038/s41571-024-00863-5Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a mediator of the cellular replication stress response that, upon activation, initiates a cascade of coordinated reactions that ultimately enables DNA repair. This biological function makes ATR an attractive therapeutic target in cancers with elevated replication stress or DNA-repair deficiency. This Review discusses the currently available results from clinical trials testing ATR inhibitors as well as challenges and solutions in the development of this therapeutic class.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Natalie Y. L. Ngoi Patrick G. Pili é Daniel J. McGrail Michal Zimmermann Katharina Schlacher Timothy A. Yap Source Type: research